Dec. 16, 2015
DigiSight Technologies, Inc., introduced the Paxos portfolio of products, including a HIPAA-compliant cloud-based portal, a vision assessment smartphone application, a mobile imaging device and analytics.
“We are excited to introduce the Paxos platform to the medical and research communities,” says Doug Foster, president and CEO of DigiSight. “Paxos is a step toward fully realizing the promise of mobile and cloud-based computing in ophthalmology. We are excited about the potential of our technology to positively impact patient engagement and improve patient care.”
The company’s Paxos product suite includes:
• A cloud-based portal that creates an outcomes-focused patient profile from data united from multiple sources in real time.
• A mobile application called Paxos Checkup, the company’s flagship vision assessment tool, available on both iOS and Android. A physician-prescribed vision testing application, Paxos Checkup offers patients multiple vision assessments, including a clinically validated visual acuity test and a dynamic Amsler grid. The app enables patients to test their visual function at home and share results automatically and securely with their physician(s).
• Paxos Scope, a hardware add-on with a mobile application that allows health care providers to capture ophthalmic photographs of patients anywhere. Paxos Scope is a combined anterior and posterior segment mobile imaging system available for smartphones, incorporating technology licensed from Stanford University. This system features secure storage, a built-in variable intensity light source for patient comfort and a universal mounting and alignment mechanism that can yield up to a 56-degree static field of view.
• Paxos Analytics, which enables real-time insight on clinical study outcomes with high-frequency longitudinal data not previously available, to be launched in 2016.
“Paxos enables physicians to monitor changes in their patients’ vision on a daily basis, which holds enormous potential for detecting disease progression that may require treatment. This technology also provides an important source of data for companies investigating new treatments in clinical trials,” says Philip J. Rosenfeld, M.D., Ph.D., of the Bascom Palmer Eye Institute in Miami, Fla. “This is especially exciting for day-to-day patient care because detection of sudden vision changes in our patients with chronic conditions will facilitate office visits and could potentially lead to preservation of vision and prevention of blindness.”
Ophthalmologists affiliated with the Himalayan Cataract Project, a non-profit organization that brings eyecare to the needlessly blind, evaluated Paxos Scope in Nepal during a high-volume cataract campaign and said they were impressed with the technology.
“It’s a game-changer, especially in terms of screening patients in remote areas,” says John Welling, M.D., Himalayan Cataract Project International Fellow. “Traditional ocular imaging equipment is not portable, and cost-prohibitive in much of the developing world. In the absence of quality image-sharing capability, patients will often be referred, which means traveling to an eye care facility – sometimes days away – to receive a proper diagnosis and subsequent treatment.
“In contrast, Paxos Scope enables a high-quality image to be sent from the point of care to a specialist within seconds. The goal is to improve patient care by harnessing technology that most of us are already carrying around in our pockets,” says Welling.
